Are Investors Undervaluing Tactile Systems Technology (TCMD) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Feb 23, 2026

3 Reasons Why Growth Investors Shouldn't Overlook Tactile Systems Technology (TCMD)

Tactile Systems Technology (TCMD) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research • Feb 20, 2026

Tactile Systems Technology (TCMD) Just Overtook the 50-Day Moving Average

Tactile Systems Technology (TCMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TCMD broke through the 50-day moving average, which suggests a short-term bullish trend.

Zacks Investment Research • Feb 19, 2026

Tactile Systems Technology (TCMD) Recently Broke Out Above the 20-Day Moving Average

Tactile Systems Technology (TCMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TCMD broke through the 20-day moving average, which suggests a short-term bullish trend.

Zacks Investment Research • Feb 19, 2026

Tactile Systems Technology Analysts Raise Their Forecasts After Better-Than-Expected Q4 Earnings

Tactile Systems reported fourth-quarter earnings of 46 cents, better than the consensus of 44 cents. Sales jumped 21% to $103.59 million, beating the Wall Street estimates of $93.80 million, attributable to lymphedema and airway clearance product lines.

Benzinga • Feb 18, 2026

Why Tactile Systems Technology Stock Surged by Nearly 18% Today

The medical devices specialist posted its final set of figures for 2025. In the fourth quarter, it grew both revenue and profitability at impressive rates.

The Motley Fool • Feb 19, 2026

Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call Transcript

Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 18, 2026

Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

LymphaTech's 3D Platform and Digital Capabilities to Improve Disease Identification, Accelerate Therapy Adoption, and Support Next-Generation Lymphatic Therapies LymphaTech's 3D Platform and Digital Capabilities to Improve Disease Identification, Accelerate Therapy Adoption, and Support Next-Generation Lymphatic Therapies

GlobeNewsWire • Feb 17, 2026

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 million Gross margin of 78% versus 75% in Q4 2024 Net income of $10.6 million versus $9.7 million in Q4 2024 Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 million Gross margin of 76%, compared to 74% in 2024 Operating cashflow of $42.8 million, compared to $40.7 million in 2024 Repaid full outstanding principal balance of $26.3 million under the Company's term loan Repurchased $26.5 million of stock at an average price of $12.36 per share Ended 2025 with $83.4 million in cash, compared to $94.4 million at the end of 2024 Recent Business Highlights Acquired LymphaTech, expanding our lymphedema solutions portfolio and strengthening our R&D capabilities with their digital 3D scanning technology for chronic swelling detection, measurement, and monitoring Announced the publication of two-month clinical data comparing Flexitouch Plus™ to usual care in the Journal of the Sciences and Specialties of the Head and Neck “In 2025, we executed with discipline against our core growth strategies, delivering double-digit revenue growth, expanding gross margin and adjusted EBITDA, and generating strong cash flow, while continuing to strategically invest in people and workflow-related processes to strengthen our business for scale,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.

GlobeNewsWire • Feb 17, 2026

Tactile Systems Technology (TCMD) Q4 Earnings and Revenues Top Estimates

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.4 per share a year ago.

Zacks Investment Research • Feb 17, 2026